ir.aptevotherapeutics.com
Investor Home : Investors : AptevoAptevo Therapeutics is a biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients' lives
http://ir.aptevotherapeutics.com/
Aptevo Therapeutics is a biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients' lives
http://ir.aptevotherapeutics.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Thursday
LOAD TIME
0.8 seconds
16x16
32x32
PAGES IN
THIS WEBSITE
0
SSL
EXTERNAL LINKS
26
SITE IP
63.150.12.56
LOAD TIME
0.781 sec
SCORE
6.2
Investor Home : Investors : Aptevo | ir.aptevotherapeutics.com Reviews
https://ir.aptevotherapeutics.com
Aptevo Therapeutics is a biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients' lives
MOR209/ES414 (anti-PSMA x anti-CD3) : Aptevo
http://aptevotherapeutics.com/mor209es414-anti-psma-x-anti-cd3
MOR209/ES414 (anti-PSMA x anti-CD3). MOR209/ES414 is a humanized, bispecific ADAPTIR molecule that binds to prostate-specific membrane antigen (PSMA) and CD3. PSMA expression is upregulated in prostate cancer and is highest in advanced, metastatic castration-resistant prostate cancer (mCRPC). The MOR209/ES414 mechanism of action is to redirect T cells to kill PSMA-expressing tumor cells. MOR209/ES414 induces potent redirected T-cell cytotoxicity of tumors in. In 2015 Aptevo Therapeutics initiated a Phase...
OTLERTUZUMAB (anti-CD37) : Aptevo
http://aptevotherapeutics.com/otlertuzumab-anti-cd37
Otlertuzumab (originally known as TRU-016) is a humanized monospecific ADAPTIR™ molecule that targets CD37. CD37 is a cell surface protein expressed on normal and transformed B cells that has been implicated in diverse cellular processes including cell adhesion, proliferation, differentiation, motility, and tumor invasion. Otlertuzumab induces cell death of primary CLL cells and B-cell tumor lines in vitro. Chronic lymphocytic leukemia (CLL). The purpose of this study is to evaluate the safety and effica...
Careers : Aptevo
http://aptevotherapeutics.com/careers
The passion to make a difference. Looking for a rewarding career at a company standing at the forefront of today’s biotech industry? Look no further Aptevo Therapeutics is attracting some of the best minds in the field. Our rich heritage of leadership and innovation combined with forward thinking makes Aptevo Therapeutics unique among its competitors.
Management Team : Aptevo
http://aptevotherapeutics.com/management-team
Marvin L. White, President and Chief Executive Officer. Jeff Lamothe, SVP and Chief Financial Officer. Scott C. Stromatt, M.D., Chief Medical Officer & SVP, Clinical Development & Medical Affairs. Randy J. Maddux, SVP Operations. Jane Gross, Ph.D., Senior Vice President and Chief Scientific Officer. Mike Adelman, VP, Commercial Operations. Shawnte Mitchell, VP, Human Resources, General Counsel and Corporate Secretary. Marvin L. White, President and Chief Executive Officer.
APVO425 (anti-ROR1 x anti-CD3) : Aptevo
http://aptevotherapeutics.com/apvo425-anti-ror1-x-anti-cd3
APVO425 (anti-ROR1 x anti-CD3). APVO425 is a humanized, bispecific ADAPTIR molecule targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1) and CD3. ROR1 is a tumor-specific antigen that is upregulated in many B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, and solid malignancies, including prostate cancer, ovarian cancer, renal cell carcinoma, non-small cell lung cancer, triple negative breast cancer (TNBC), and pancreatic cancer.
Commercial Products : Aptevo
http://aptevotherapeutics.com/commercial-products
Novel treatments for people with bleeding disorders and cancer. At Aptevo Therapeutics, we take pride in our products that treat rare bleeding disorders and other conditions. This feeling comes not only from creating and offering various treatments. It grows from a deep understanding of patient communities. Hearing the stories that drive our connection to what people want and need from therapy and beyond. To us, that’s at the heart of innovation. Our established portfolio of market products.
Pipeline : Aptevo
http://aptevotherapeutics.com/pipeline
Innovation is at the heart of our product portfolio. Pipeline is available for partnering opportunities (other than MOR209/ES414). Otlertuzumab, originally known as TRU-016 (anti-CD37). MOR209/ES414 (anti-PSMA x anti-CD3). APVO425 (anti-ROR1 x anti-CD3). Additional RTCC assets (targets not disclosed). Otlertuzumab, originally known as TRU-016 (anti-CD37). MOR209/ES414 (anti-PSMA x anti-CD3). APVO425 (anti-ROR1 x anti-CD3). Additional RTCC assets (targets not disclosed). ES210 (anti-CD86 x monoIL-10).
Board of Directors : Aptevo
http://aptevotherapeutics.com/board-of-directors
Marvin L. White. Daniel J. Abdun-Nabi. Grady Grant, III. Zsolt Harsanyi, Ph.D. John E. Niederhuber, M.D. Marvin L. White. Daniel J. Abdun-Nabi. Grady Grant, III. Mr Grant is the Vice President of Medical Sales for Mead Johnson Nutrition, a public company focused on pediatric nutrition. He has held this position since December 2011, preceded by 30 years of service at Eli Lilly and Company which includes his service as Vice President of Sales Neuroscience from January 2006 to December 2011.
ES210 (anti-CD86 x monoIL-10) : Aptevo
http://aptevotherapeutics.com/es210-anti-cd86-x-monoil-10
ES210 (anti-CD86 x monoIL-10). ES210 is a humanized, targeted cytokine therapeutic under development for the treatment of ulcerative colitis and has potential utility in multiple autoimmune diseases. ES210 was engineered using our bispecific ADAPTIR. Technology platform to deliver a modified form of the immunosuppressive cytokine IL-10 to antigen-presenting cells by targeting CD86. ES210 is designed to suppress T-cell responses through inhibition of antigen presentation. T-cell expansion measured as % hu...
TOTAL LINKS TO THIS WEBSITE
26
Investor Overview | AppFolio, Inc.
We create easy-to-use, cloud-based software that helps small and mid-sized businesses more effectively market, manage and grow their business. Today, our products serve the legal and property management industries. 160; 0.35. AppFolio, Inc. Announces Second Quarter 2015 Financial Results. AppFolio, Inc. Announces Date of Second Quarter 2015 Financial Results Release. AppFolio, Inc. Announces Exercise and Closing of Over-Allotment Option for Initial Public Offering. There are currently no events scheduled.
Corporate Overview - Apple Hospitality Reit
RESIDENCE INN, BURBANK, CALIFORNIA. Apple Hospitality REIT, Inc. (NYSE: APLE) owns one of the largest portfolios of upscale, select service hotels in the United States. Our national, geographically diverse portfolio consists of 235 Hilton. Branded hotels located across 33 states, serving some of the country’s top markets for business and leisure travelers. And our hotels operate exclusively under some of the nation’s leading brands: Courtyard by Marriott. Fairfield Inn by Marriott. Hampton Inn by Hilton.
Investor Relations Home | Applied Industrial Technologies | Applied.com
Applied Industrial Technologies is a leading North American distributor of industrial products and services. Why Invest in Applied? E-mail the Board of Directors. Q4 2015 Applied Industrial Technologies Earnings Conference Call. 160;at 10:00 am ET. Q4 2015 Applied Industrial Technologies Earnings Conference Call. Wednesday, August 12, 2015 . 10:00 am ET . Click here for webcast. Click here to add this event to your calendar. 160; 0.23. Data as of 08/07/15 4:00 pm ET. Minimum 20 minute delay. CLEVELAND, ...
Approach Resources - Investors
Approach Resources Inc. (NASDAQ: AREX) is an independent oil and gas company headquartered in Fort Worth, Texas. Our operations are focused on exploration, development, production and acquisition of oil and gas properties. We own a leading position in the southern Midland Basin of the greater Permian Basin in West Texas, where we are developing the horizontal Wolfcamp shale oil play. Approach Resources Inc. Reports Second Quarter 2015 Results. View All News Releases. Abundant, Low-cost drilling targets.
Investor Home | Investors | Apricus Biosciences
Mission / Vision / Values. Annual Meeting of Stockholders. Apricus Biosciences, Inc. at the Canaccord Genuity 35th Annual Growth Conference. 160;at 10:00 am ET. Apricus Biosciences, Inc. at the Canaccord Genuity 35th Annual Growth Conference. Wednesday, August 12, 2015 . 10:00 am ET . Click here for webcast. Click here to add this event to your calendar. Apricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in Twelve Additional Countries. RayVa Phase 2a Trial Top...
Investor Home : Investors : Aptevo
Aptevo Therapeutics and the ADAPTIR (Modular Protein Technology) Platform: The Future of Immuno-oncology. 160; 0.08 (3.21%). Updated January 13, 2017 4:00 pm ET. Stacey L. Jurchison. Senior Director, Investor Relations and Corporate Communications. Aptevo Therapeutics Inc at 29th Annual ROTH Conference. Aptevo Therapeutics Inc at the 16th Annual PEPTALK Conference. Aptevo Therapeutics Inc at Piper Jaffray 28th Annual Healthcare Conference.
A+ Asia Pacific Telecom Website
Aptose Biosciences - Investors - Overview
SELECT SOLID TUMOR INDICATIONS. CDX2 AND KRUPPEL-LIKE FACTOR BIOLOGY. Aptose Biosciences, Inc. at 9th Annual Biotech Showcase. January 10, 2017. 160;at 9:00 am PT. Aptose Biosciences, Inc. at 9th Annual Biotech Showcase. Tuesday, January 10, 2017 . 9:00 am PT . Click here for webcast. Click here to add this event to your calendar. January 5, 2017. Aptose Biosciences to Present at Biotech Showcase 2017 Conference. December 29, 2016. Aptose Biosciences Provides Update on APTO-253 Development.
AQR Capital - Investor Relations - Overview
Investor and Media Contact. There are currently no news releases. Primary IR and Media Contact. Quotes delayed at least 15 minutes. Market data provided by Interactive Data. Powered and implemented by Interactive Data Managed Solutions.
Investor Relations | Aqua America
Skip to main navigation. Reconciliation of GAAP to Non-GAAP Financial Measures. Regulated segment - Efficiency ratio adjusted for purchased water. Reconciliation of GAAP to Non-GAAP financial measures - EBITDA reconciliation for continuing operations. Adjusted Net Income EPS Q4 2017. Dividend Reinvestment and DSPP. There are currently no events to display. Feb 27, 2018. Aqua America Reports Earnings for 2017, Announces 2018 Guidance. Feb 5, 2018. Aqua America Declares March 2018 Dividend. Feb 1, 2018.
Arafa Holding | Investor Relations
Board and Shareholders Actions. Share and Corporate Information. Luxury, Formal and Casual Wear across own brands. Textiles, Apparel and Tailoring, Retail and Distribution. Concrete, with 47 retail stores nationwide across Egypt. Learn about Arafa Holding's business model, strategy, brands and partnerships through our downloadable presentations in the Presentations and Publications center. As of 16:02, on Thu, Aug, 13 2015. Arafa Earnings Release 1Q2015. Arafa Holding Financials 1Q2015 (Arabic).
